Safety of combined longacting injectable cabotegravir and longacting injectable rilpivirine in virologically suppressed adolescents with HIV IMPAACT 2017MOCHA a phase 12 multicentre openlabel noncomparative dosefinding study

Simple item page
dc.article.end-page200en
dc.article.start-page191en
dc.citation.doi10.1016/S2352-3018(24)00344-8en
dc.contributor.authorCarolyn Mooreen
dc.contributor.authorKristin Baltrusaitisen
dc.contributor.authorBrookie Besten
dc.contributor.authorJohn Moyeen
dc.contributor.authorAvyi Violarien
dc.contributor.authorFaeezah Allyen
dc.contributor.authorMrinmayee Dharen
dc.contributor.authorE et alen
dc.date.accessioned2026-04-22T18:14:00Z
dc.departmentWITS REPRODUCTIVE HEALTH AND HIV INSTITUTEen
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/49093
dc.journal.titleSafety of combined longacting injectable cabotegravir and longacting injectable rilpivirine in virologically suppressed adolescents with HIV IMPAACT 2017MOCHA a phase 12 multicentre openlabel noncomparative dosefinding studyen
dc.journal.volume12en
dc.titleSafety of combined longacting injectable cabotegravir and longacting injectable rilpivirine in virologically suppressed adolescents with HIV IMPAACT 2017MOCHA a phase 12 multicentre openlabel noncomparative dosefinding studyen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
600.63 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)